Y. Wang

Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study

K. Papp, M. Sundaram, Yihua Gu, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis

K. Reich, U. Mrowietz, R. Langley, 2010 .

Changes in C‐reactive protein in patients with moderate‐to‐severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy

B. Strober, Y. Poulin, D. Williams, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

G. Wang, J. Zheng, M. Okun, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

K. Kragballe, K. Reich, C. Griffiths, 2013, The British journal of dermatology.

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial

M. Lebwohl, K. Papp, Chenglong Han, 2010, The British journal of dermatology.

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

Y. Wang, U. Mrowietz, Kristian Reich, 2013, The British journal of dermatology.

PSY6 USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS

A. Kimball, R. Langley, Y. Wang, 2009 .